Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration

Purpose Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the eff...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2018-03, Vol.41 (3), p.325-331
Main Authors: Bizzarri, C., Lonero, A., Delvecchio, M., Cavallo, L., Faienza, M. F., Giordano, M., Dello Strologo, L., Cappa, M.
Format: Article
Language:English
Subjects:
Body height
Children
Endocrinology
Growth hormones
Growth rate
Kidney diseases
Kidneys
Medicine
Medicine & Public Health
Metabolic Diseases
Nutritional status
Original Article
Physical growth
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p  
ISSN:1720-8386
0391-4097
1720-8386
DOI:10.1007/s40618-017-0745-4